The article focuses on research into the role of the microbiome and intestinal bacteria in patient response to immunotherapies and the development of cancer or other diseases. It states researchers studying mice found two bacterial species from the Bifidobacterium (B.) genus improved antitumor activity, B. breve and B. longum, with mice with the bacterial strains with an improved response to a immunotherapy drug. It considers the potential impact of antibiotics in killing beneficial bacteria.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados